A multicenter, randomized, open-label, phase III study of anlotinib plus CAPEOX versus bevacizumab plus CAPEOX as first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer-MedSci.cn

A multicenter, randomized, open-label, phase III study of anlotinib plus CAPEOX versus bevacizumab plus CAPEOX as first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer

Ding, K; Liu, Y; Song, Y; Xu, D; Li, J; Wang, J; Chen, X; Lin, R; Jiang, Y; Zhang, Y; Zhang, W; Cheng, Y; Wu, X; Yuan, Y

ANNALS OF ONCOLOGY, 2022; 33 (7): S736

科室
- - 订阅+
  - 更多科室
工具
服务